Compare iShares Core MSCI EAFE ETF (IEFA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs ResMed Inc. — how do they compare? iShares Core MSCI EAFE ETF trades at $96.21 (market cap $189.19B), while ResMed Inc. trades at $229.95 (market cap $31.89B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 5.9× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI EAFE ETF for 41 Days and ResMed Inc. for 51 Days on average.
| IEFA | RMD | |
|---|---|---|
Market Cap | $189.19B | $31.89B |
Volume | 8,441,787 | 618,314 |
Sector | Broad Market / Factor | Health |
52-Week High | $101.41 | $277.88 |
52-Week Low | $85.06 | $182.82 |
Typical Hold Time | 41 Days | 51 Days |
Enterprise Value | — | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with a bearish technical signal. The ETF manages $196 billion in assets, focusing on developed markets outside North America. Recent comparisons highlight its higher dividend yield versus competitors but lower recent performance than some peers. Technical indicators show oversold conditions with RSI at 28.63, while moving averages remain bearish with key support at $95.
The outlook remains cautious given bearish technical momentum and competitive pressure from lower-cost alternatives. International diversification benefits are offset by underperformance relative to global and emerging market ETFs. Key risks include currency fluctuations and concentrated U.S. market exposure driving defensive shifts.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
